Request Pricing

Global Infectious Disease Situation Update

Reporting Period: March 15-31, 2026

The AeroClenz Chief Medical Officer periodically reviews publicly available infectious disease surveillance reports from organizations such as the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), and European Centre for Disease Prevention and Control (ECDC).

These summaries are intended to provide general awareness of global infectious disease activity relevant to international travel, healthcare systems, and high-traffic indoor environments.

This information is provided for situational awareness only and does not constitute medical advice.

Key Takeaways

For the period of March 15-31, 2026, several notable global infectious disease trends were observed:

• Measles continues to present a significant disruption risk due to high transmissibility and outbreak concentration
• Seasonal respiratory viruses are declining globally but remain active
• Cholera activity persists across multiple regions, with increasing mortality in some settings
• Mpox continues to circulate globally, including emerging clade patterns
• Travel-associated arboviral diseases, including chikungunya and dengue, remain relevant

Top 5 Signals

1) Measles remains the highest disruption risk per case

The CDC reported 1,362 confirmed measles cases in the United States as of March 12, 2026, with cases concentrated in outbreak settings.

Measles continues to combine high transmissibility with the potential for rapid spread across travel networks. The need for contact tracing and coordination across jurisdictions contributes to its ongoing operational significance.

2) Respiratory viruses are declining but still active

WHO surveillance indicates that influenza activity continues to decline globally, with positivity around 10% in week 11, while SARS-CoV-2 remains low and RSV activity is stable at low levels.

Across Europe, ECDC reports similar trends, with influenza and RSV still circulating but decreasing. Severe influenza continues to affect older adult populations disproportionately.

3) Cholera remains a high-impact, multi-country concern

WHO reported 18,715 cholera and acute watery diarrhea cases and 269 deaths in February 2026 across 17 countries, with deaths increasing compared to January.

Cholera risk remains closely tied to water, sanitation, and healthcare infrastructure conditions in affected regions.

4) Mpox remains an active global signal

WHO reporting indicates that 50 countries reported 1,334 confirmed mpox cases in January 2026, with the majority of cases occurring in the WHO African Region.

Ongoing transmission, including clade Ib activity and recombinant strain monitoring, highlights the importance of continued surveillance.

5) Travel-related arboviral risk remains relevant

Chikungunya activity in the Seychelles continues to be monitored by CDC and ECDC, with guidance emphasizing mosquito precautions for travelers.

Dengue also remains a significant background concern, with PAHO reporting more than 250,000 suspected cases in the Americas by early March 2026.

Global Situation Overview

Respiratory Viruses

The global respiratory disease picture remains influenza-led rather than COVID-led.

WHO data from March indicates:

• Influenza positivity declining but still present globally
• SARS-CoV-2 activity remaining low
• RSV stable and low

Regional data from Europe reflects similar trends, with declining but ongoing circulation of influenza and RSV.

Measles

Measles remains one of the most operationally significant infectious diseases due to its combination of:

• High transmissibility
• Amplification through travel
• Resource-intensive contact tracing

CDC data confirms continued outbreak activity in 2026, alongside evidence of declining vaccination coverage in some populations.

Air Travel and Measles Exposure

Published analyses, including those from the Journal of Travel Medicine, continue to show that measles transmission during air travel can extend beyond immediate seating proximity.

Investigations across more than 180 flights have identified secondary cases both within and outside defined contact zones, with a high proportion occurring among unvaccinated individuals.

These findings highlight the complexity of exposure management in travel environments.

Cholera

Cholera continues to be reported across multiple regions, particularly in areas with limited water and sanitation infrastructure.

Recent updates indicate increasing mortality in some settings, suggesting ongoing challenges in outbreak control and access to care.

External factors, including disruptions to aid delivery and logistics constraints, may further complicate response efforts in affected regions.

Mpox

Mpox continues to be reported globally, with current surveillance focusing on:

• Clade Ib transmission patterns
• Monitoring of recombinant viral strains
• Risk differences across population groups

Public-health agencies continue to assess risk as higher in defined networks with close contact and lower for the general population without specific exposure risks.

Arboviruses: Chikungunya and Dengue

Chikungunya transmission in the Seychelles and surrounding regions remains relevant for travel-associated exposure.

Public-health agencies continue to emphasize:

• Mosquito bite prevention
• Awareness of regional activity

Dengue remains a significant global burden, particularly in the Americas, with case counts continuing to accumulate through early 2026.

High-Consequence Pathogens

Nipah virus:
Recent clusters in India and Bangladesh remain contained, with no evidence of sustained transmission.

Ebola and Marburg viruses:
No active outbreaks have been reported during this period. Recent outbreaks have been declared contained following appropriate monitoring intervals.

While the probability of widespread transmission remains low, these pathogens continue to be monitored due to their potential severity.

Summary

The global infectious disease landscape for mid-March 2026 reflects declining respiratory virus activity alongside continued monitoring of high-impact and travel-associated risks.

Key themes include:

• Measles as the highest disruption risk per individual case
• Improving but still active respiratory virus trends
• Persistent cholera activity in infrastructure-limited regions
• Continued mpox transmission and viral evolution monitoring
• Ongoing relevance of travel-associated arboviral diseases

Public-health surveillance agencies continue to monitor these developments and publish updates as new information becomes available.

Sources referenced in this summary include the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), the European Centre for Disease Prevention and Control (ECDC), and peer-reviewed literature, including the Journal of Travel Medicine.

To learn more about AeroClenz, visit www.aeroclenz.com. Follow AeroClenz on social media for updates on research and technology developments.LinkedIn: https://www.linkedin.com/company/aeroclenz
Facebook: https://www.facebook.com/AeroClenz
Instagram: https://www.instagram.com/aeroclenz

Get Updates Automatically
Translate »
Scroll to Top

Michael Stroup

Chief Operations Officer

Michael is a results-driven leader with 20 years of experience improving operations to achieve greater organizational effectiveness, productivity, and performance across multiple industries. Most recently Michael served as Integration Engineering Manager at CooperSurgical, a leading fertility medical device manufacturer. Prior to CSI, he has a proven track record of driving operational and engineering excellence within medical device, food, electronics and automotive industries by leading day to day operations and providing effective strategic leadership/execution.  His expertise includes, but is not limited to, global production set up, process improvements, machinery design and compliance. Michaels holds a Bachelor of Science in Mechanical Engineering Technology and Industrial Automotive Technology from Indiana State University and a Master of Science in Industrial Technology from Indiana State University.

Matt Saberton

CEO, Founder, Co-Inventor

Matt has been passionate about aviation from a young age, earning his private pilot’s license in high school. After obtaining a degree in Aviation and Aerospace Science, he began his career as a flight instructor and then became an air ambulance pilot, where he recognized the importance of cabin cleanliness.

Rising through the ranks at one of the largest worldwide charter airlines, Matt became Captain and later Chief Pilot, gaining deep insights into maintaining safe environments in aviation. This experience led him to found Aeroclenz, Inc., where he now serves as CEO.

Under his leadership, Aeroclenz has transitioned from an aerospace-focused company to a leader in UV disinfection solutions, offering custom products for both aerospace and terrestrial indoor applications. While the company’s roots are in aviation, its technologies now ensure high standards of cleanliness across various industries.

Jameson Trettenero

Director of Marketing

Jameson is a seasoned marketing expert with experience driving strategic marketing initiatives across a diverse array of industries. In his role, Jameson leads the marketing efforts with a focus on innovative growth strategies, brand elevation, and data-driven decision-making that align with the company’s overarching business goals.

Before joining Aeroclenz, Jameson held key leadership positions at top-tier digital agencies. In his agency experience, he spearheaded multi-divisional teams across disciplines including SEO, Paid Media, Analytics, and Creative. His strategic oversight and client-centric approach significantly enhanced client retention and business growth, particularly across enterprise-level accounts.

Jameson’s expertise extends to managing complex client relationships, advising C-level executives, and navigating the intricacies of the marketing landscape. His ability to harmonize creativity with analytics has consistently driven measurable success for clients, from Fortune 500 companies to emerging brands.